Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for adults with elevated LDL cholesterol in the United States. Its marketed portfolio includes NEXLETOL and NEXLIZET, oral once-daily non-statin tablets used in patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia and cardiovascular disease who need additional LDL-C reduction. The company also markets NILEMDO, an ACL inhibitor, and NUSTENDI, a bempedoic acid and ezetimibe tablet for elevated LDL-C. Esperion has collaboration and license agreements with Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Europe GmbH. Incorporated in 2008 and formerly known as HDL Therapeutics, Inc., the company is headquartered in Ann Arbor, Michigan.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ESPR
|
—
|
—
|
—
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
—
|
August 4, 2026
|
-110.4x
|
-2.7x
|
2.0x
|
819.5 M
|
—
|
39.9%
|
91.0%
|
-2.5
|
—
|
247.6%
|
